{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002622","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2022-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.057899+00:00","generated_at":"2026-06-27T02:30:37.053509+00:00","sec_items":["5.02","8.01","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Equillium appoints Dr. Barbara Troupin, former Myokardia SVP, to Board","bullets":["Appointed Dr. Barbara Troupin, M.D., as a class I director, effective February 24, 2022.","Will serve on the Nominating and Corporate Governance Committee.","Dr. Troupin was most recently SVP at Myokardia; prior CMO at ERX Pharmaceuticals, Aquinox, Apricus Biosciences.","Chairman cited her experience as Equillium prepares to initiate Phase 3 study in aGVHD and expand programs with Bioniz assets."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002622","json":"https://secwatch.observer/filing/0000950170-22-002622.json","markdown":"https://secwatch.observer/filing/0000950170-22-002622.md","text":"https://secwatch.observer/filing/0000950170-22-002622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/0000950170-22-002622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/eq-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:30:37.053509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e149a5e8a4","claim":"Dr. Barbara Troupin was appointed as Director at Equillium, Inc..","evidence_excerpt":"Effective February 24, 2022, the Board increased the number of directors to nine and appointed Dr. Barbara Troupin, M.D., as a class I director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000095017022002622/0000950170-22-002622-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}